SAN ANTONIO, TX - The oral mammalian target of rapamycin inhibitor everolimus combined with the steroidal aromatase inhibitor exemestane significantly improves the overall response rate in postmenopausal women with advanced breast cancer, according to data released at the 37th Annual San Antonio Breast Cancer Symposium (SABCS).
More...